Unknown PHASE1 INTERVENTIONAL 1-arm NCT03208556

Safety and Efficacy of iPD1 CD19 eCAR T Cells in Relapsed or Refractory B-cell Lymphoma

Pilot Study of Autologous Anti-CD19 4-1BB CAR T Cells With Cell-intrinsic PD1 Inhibition in Relapsed or Refractory B-cell Lymphoma

Sponsor: Marino Biotechnology Co., Ltd.

Conditions Relapsed or Refractory B-cell Lymphoma

Interventions Fludarabine and cyclophosphamide iPD1 CD19 eCAR T cells

Updated 6 times since 2017 Last updated: Sep 12, 2017 Started: Jun 21, 2017 Primary completion: Jun 1, 2019 Completion: Jun 1, 2020

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT03208556, this PHASE1 trial focuses on Relapsed or Refractory B-cell Lymphoma and remains ongoing. Sponsored by Marino Biotechnology Co., Ltd., it has been updated 6 times since 2017, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Unknown PHASE1
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE1

Status: Unknown Status → Unknown
Jan 2021 — Jul 2024 [monthly]

Unknown Status PHASE1
Jul 2020 — Jan 2021 [monthly]

Unknown Status PHASE1

Status: Recruiting → Unknown Status
Jun 2018 — Jul 2020 [monthly]

Recruiting PHASE1

▶ Show 1 earlier version

Aug 2017 — Jun 2018 [monthly]

Recruiting PHASE1

First recorded

Jun 2017

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Marino Biotechnology Co., Ltd.
Peking University

Data source: Peking University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Beijing, China